原发性喉癌血清COX-2 PTTG1 TLR4水平与临床病理特征及预后生存状况的关系探讨

doi:10.3969/j.issn.1006-6233.2024.09.021

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1441 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the relationship between serum cyclooxygenase-2 (COX-2), pituitary tumor transforming gene 1 (PTTG1), toll-like receptor 4 (TLR4) levels and clinicopathological features, prognosis, and survival of primary laryngeal cancer.Methods: A total of 105 patients with primary laryngeal cancer and 105 patients with benign laryngeal lesions in Dazhou City Central Hospital of Sichuan Province from May 2021 to March 2023 were selected as observation and control groups, respectively. The serum COX-2, PTTG1 and TLR4 levels of the two groups were compared, and the relationship between serum COX-2, PTTG1 and TLR4 levels, and clinicopathological features was analyzed using multiple linear regression, and the prognostic survival rate of the patients with different serum COX-2, PTTG1, and TLR4 levels was compared in the follow-up of 3 years.Results: The levels of COX-2, PTTG1, and TLR4 in the observation group were (38.89±12.14) ng/L, (140.17±30.25) pg/mL, and (13.94±3.25) ng/mL, respectively, which were higher than those in the control group (17.63±5.09) ng/L, (98.49±15.63) pg/mL, and (8.72±2.13) ng/mL (t=16.549, 12.543, 13.765, all P<0.05). Multiple linear regression analysis showed that clinical stage (partial regression coefficient:0.714, 0.722, 0.719), tumor differentiation degree (partial regression coefficient:0.756, 0.749, 0.798), and lymph node metastasis (partial regression coefficient:0.802, 0.798, 0.713) were the influencing factors for the levels of serum COX-2, PTTG1, and TLR4 in patients with primary laryngeal cancer (P<0.05). The 3-year overall survival rate and overall survival rate of the COX-2 high-level subgroup were 80.77% and 71.15%, respectively, which were significantly higher than those of the low-level subgroup 95.83% and 87.50% (P<0.05); the 3-year overall survival rate and overall survival rate of the PTTG1 high-level subgroup were 80.39% and 68.63%, respectively, which were significantly higher than those of the low-level subgroup 95.92% and 89.80% ( P<0.05); 3-year overall survival rate and overall survival rate of TLR4 high-level subgroup were 78.85% and 71.15%, respectively, which were significantly higher than those of 97.92% and 87.50% in the low-level subgroup (P<0.05).Conclusion: The levels of serum COX-2, PTTG1, and TLR4 are high in patients with primary laryngeal cancer, and their high levels are related to clinical stage, tumor differentiation, and lymph node metastasis. Detection of COX-2, PTTG1, and TLR4 levels can reflect the prognosis and survival of patients to a certain extent.

Key words： Primary laryngeal carcinoma Pathological features Prognosis survival COX-2 PTTG1 TLR4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Jian
	YANG Ling
	WANG Dong

Cite this article:

WU Jian,YANG Ling,WANG Dong. Relationship between Serum COX-2 PTTG1 TLR4 Levels and Clinicopathological Features Prognosis and Survival of Primary Laryngeal Carcinoma[J]. HeBei Med, 2024, 30(9): 1525-1529.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2024.09.021 OR http://www.hbyxzzs.cn/EN/Y2024/V30/I9/1525

[1] Kurten CHL,Zioga E,Gauler T,et al.Patterns of cervical lymph node metastasis in supraglottic laryngeal cancer and therapeutic implications of surgical staging of the neck[J].Eur Arch Otorhinolaryngol,2021,278(12):5021-5027.
[2] Lin ZY,Lin HQ,Chen YQ,et al.Long-term survival trend after primary total laryngectomy for patients with locally advanced laryngeal carcinoma[J].Cancer,2021,12(4):1220-1230.
[3] Wang Z,Gu J,Yan AH,et al.Downregulation of circ-RANBP9 in laryngeal cancer and its clinical significance[J].Ann Transl Med,2021,9(6):484-491.
[4] Ansorge N,Dannecker C,Jeschke U,et al.Combined COX-2/PPARγ expression as independent negative prognosticator for vulvar cancer patients[J].Diagnostics (Basel),2021,11(3):491-495.
[5] Ceylan O,Caglar O.Importance of COX-2 expression in wilms' tumour:a preliminary study[J].Int Clin Pract,2021,75(6):141-146.
[6] Parte S,Virant-Klun I,Patankar M,et al.PTTG1:a unique regulator of stem/cancer stem cells in the ovary and ovarian cancer[J].Stem Cell Rev Rep,2019,15(6):866-879.
[7] Ren JH,He JY,Zhang HJ,et al.Platelet TLR4-ERK5 axis facilitates NET-mediated capturing of circulating tumor cells and distant metastasis after surgical stress[J].Cancer Res,2021,81(9):2373-2385.
[8] Burgueno JF,Fritsch J,Gonzalez EE,et al.Epithelial TLR4 signaling activates DUOX2 to induce microbiota-driven tumorigenesis[J].Gastroenterology,2021,160(3):797-808.
[9] Pu D,Yin LY,Huang L,et al.Cyclooxygenase-2 inhibitor:a potential combination strategy with immunotherapy in cancer[J].Front Oncol,2021,26(11):6375-6384.
[10] 曾宝辉,过新民,郭顺华.乳腺癌中垂体瘤转化基因1对免疫浸润的影响及其预后价值[J].中国普通外科杂志,2022,31(11):1483-1492.
[11] 张志轩,王晓晔,谭晓晔.喉癌患者血清垂体肿瘤转化基因表达水平与临床病理特征及预后的相关性[J].临床耳鼻咽喉头颈外科杂志,2020,34(12):1128-1131.
[12] Seo YD,Lu H,Black G,et al.Toll-like receptor 4 agonist injection with concurrent radiotherapy in patients with metastatic soft tissue sarcoma:a phase 1 nonrandomized controlled trial[J].JAMA Oncol,2023,9(12):1660-1668.
[13] 程耿,张朝阳,万莉,等.miR-519d-3p通过调控Toll样受体4/核因子-κB信号通路对前列腺癌细胞的影响机制研究[J].中国性科学,2023,32(1):39-43.